Modeling genetic risk of breast cancer

JAMA

Volumn 297, Issue 23, 2007, Pages 2637-2639

  Kauff, Noah D ^a   Offit, Kenneth ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER GENETICS; CANCER MODEL; CANCER RISK; CANCER SUSCEPTIBILITY; EDITORIAL; FAMILIAL CANCER; GENE MUTATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOCHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PATHOLOGY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; BIOLOGICAL MODEL; BREAST TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; MUTATION; NOTE; PROBABILITY; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, GENETIC; MUTATION; PROBABILITY; RISK ASSESSMENT;

EID: 34250628358     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.23.2637     Document Type: Editorial

References (20)

1. Offit K, Brown K. Quantitating familial cancer risk: a resource for clinical oncologists. J Clin Oncol. 1994;12:1724-1736.
2. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996. J Clin Oncol. 1996;14:1730-1736.
3. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23:8469-8476.
4. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75-89.
5. National Institute for Health and Clinical Excellence. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. http://www.nice.org.uk/guidance/cg41. Accessed May 23, 2007.
6. Weitzel JN, Lagos VI, Cullinane CA, et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA. 2007;297:2587-2595.
7. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10 000 individuals. J Clin Oncol. 2002;20:1480-1490.
8. Couch FJ, DeShano ML, Blackwood A, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997;336:1409-1415.
9. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998;62:145-158.
10. Robson M. Is breast conservation a reasonable option for women with BRCA-associated breast cancer? Nat Clin Pract Oncol. 2007;4:10-11.
11. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397-2406.
12. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: the Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676-689.
13. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23:1111-1130.
14. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20:2310-2318.
15. Foulkes WD, Kelly Metcalfe K, Sun P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004;10:2029-2034.
16. Satagopan JM, Boyd J, Kauff ND, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res. 2002;8:3776-3781.
17. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643-646.
18. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283:2260-2265.
19. Kauff ND, Mitra M, Robson ME, et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation negative hereditary breast cancer families. J Natl Cancer Inst. 2005;97:1382-1384.
20. Domchek SM, Eisen A, Calzone K, et al. Application of breast cancer risk prediction models in clinical practice. J Clin Oncol. 2003;21:593-601.